Novel |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
- mTORC1-mediated signalling
- Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
|
|
|
Novel |
NRG1 |
neuregulin 1 |
- Signaling by ERBB2
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PI3K events in ERBB4 signaling
- SHC1 events in ERBB4 signaling
- Nuclear signaling by ERBB4
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Downregulation of ERBB2:ERBB3 signaling
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Downregulation of ERBB2 signaling
- Long-term potentiation
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 TMD/JMD mutants
|
|
|
Novel |
OR51B4 |
olfactory receptor family 51 subfamily B member 4 |
- Olfactory Signaling Pathway
|
|
|
Novel |
PPP2CB |
protein phosphatase 2 catalytic subunit beta |
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Spry regulation of FGF signaling
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Integration of energy metabolism
- PP2A-mediated dephosphorylation of key metabolic factors
- DARPP-32 events
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- ERK/MAPK targets
- ERKs are inactivated
- MASTL Facilitates Mitotic Progression
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- CTLA4 inhibitory signaling
- Platelet sensitization by LDL
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Signaling by GSK3beta mutants
- S33 mutants of beta-catenin aren't phosphorylated
- S37 mutants of beta-catenin aren't phosphorylated
- S45 mutants of beta-catenin aren't phosphorylated
- T41 mutants of beta-catenin aren't phosphorylated
- APC truncation mutants have impaired AXIN binding
- AXIN missense mutants destabilize the destruction complex
- Truncations of AMER1 destabilize the destruction complex
- RHO GTPases Activate Formins
- RAF activation
- Negative regulation of MAPK pathway
- Regulation of TP53 Degradation
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Mitotic Prometaphase
- Cyclin D associated events in G1
- Cyclin A/B1/B2 associated events during G2/M transition
- Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
- EML4 and NUDC in mitotic spindle formation
|
|
|
Novel |
SHB |
SH2 domain containing adaptor protein B |
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
|
|
|
Novel |
TPMT |
thiopurine S-methyltransferase |
- Methylation
- Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency)
|
|
- Thiopurine S-methyltransferase deficiency (TPMT deficiency)
|
Novel |
ZFYVE1 |
zinc finger FYVE-type containing 1 |
|
|
|
|
BNIP2 |
BCL2 interacting protein 2 |
|
|
|
|
CDH1 |
cadherin 1 |
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Integrin cell surface interactions
- Apoptotic cleavage of cell adhesion proteins
- Adherens junctions interactions
- RHO GTPases activate IQGAPs
- InlA-mediated entry of Listeria monocytogenes into host cells
|
|
- Gastric cancer
- Penile cancer
- Nasopharyngeal cancer
- Breast cancer
- Hepatocellular carcinoma
- Thyroid cancer
|
|
CREBBP |
CREB binding protein |
- Regulation of gene expression by Hypoxia-inducible Factor
- RORA activates gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- PPARA activates gene expression
- PPARA activates gene expression
- Formation of the beta-catenin:TCF transactivating complex
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- HATs acetylate histones
- Attenuation phase
- Notch-HLH transcription pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- SUMOylation of transcription cofactors
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- CD209 (DC-SIGN) signaling
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- Activation of the TFAP2 (AP-2) family of transcription factors
- RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- Estrogen-dependent gene expression
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- FOXO-mediated transcription of cell death genes
- Regulation of FOXO transcriptional activity by acetylation
- Regulation of FOXO transcriptional activity by acetylation
|
- 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE
|
- Rubinstein-Taybi syndrome
|
|
CRK |
CRK proto-oncogene, adaptor protein |
- ARMS-mediated activation
- ARMS-mediated activation
- Downstream signal transduction
- Regulation of actin dynamics for phagocytic cup formation
- p130Cas linkage to MAPK signaling for integrins
- VEGFA-VEGFR2 Pathway
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- MET activates RAP1 and RAC1
- MET receptor recycling
- Regulation of signaling by CBL
- FCGR3A-mediated phagocytosis
|
|
|
|
CTPS2 |
CTP synthase 2 |
- Interconversion of nucleotide di- and triphosphates
|
|
|
|
EPHA4 |
EPH receptor A4 |
- EPH-Ephrin signaling
- EPH-Ephrin signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- EPH-ephrin mediated repulsion of cells
|
|
|
|
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
- Signaling by ERBB2
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Downregulation of ERBB2:ERBB3 signaling
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D induced cell migration and growth-cone collapse
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Constitutive Signaling by Overexpressed ERBB2
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
|
- Trastuzumab
- Lapatinib
- IGN311
- Trastuzumab emtansine
- Varlitinib
- AV-412
- Pertuzumab
- Afatinib
- Tucatinib
- Tesevatinib
- Fostamatinib
- Brigatinib
- Margetuximab
- Zanubrutinib
|
- Choriocarcinoma
- Pancreatic cancer
- Gastric cancer
- Bladder cancer
- Endometrial Cancer
- Ovarian cancer
- Cholangiocarcinoma
- Breast cancer
- Cervical cancer
|
|
ERBB3 |
erb-b2 receptor tyrosine kinase 3 |
|
|
- Lethal congenital contractural syndrome (LCCS)
- Type I diabetes mellitus
|
|
FBXO7 |
F-box protein 7 |
- Neddylation
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
FDPS |
farnesyl diphosphate synthase |
- Cholesterol biosynthesis
- Activation of gene expression by SREBF (SREBP)
|
- Pamidronic acid
- Zoledronic acid
- Alendronic acid
- Ibandronate
- Risedronic acid
- Dimethylallyl Diphosphate
- Isopentyl Pyrophosphate
- Geranyl Diphosphate
- ISOPENTENYL PYROPHOSPHATE
- Incadronic acid
- Minodronic acid
- Farnesyl diphosphate
- Geranylgeranyl diphosphate
|
|
|
FGF1 |
fibroblast growth factor 1 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Signaling by activated point mutants of FGFR1
- Signaling by activated point mutants of FGFR3
- FGFR4 ligand binding and activation
- FGFR1b ligand binding and activation
- FGFR3b ligand binding and activation
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR2b ligand binding and activation
- FGFR3 mutant receptor activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Downstream signaling of activated FGFR1
- SHC-mediated cascade:FGFR1
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- Signaling by FGFR1 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by FGFR2 IIIa TM
- Signaling by FGFR3 point mutants in cancer
|
- Pentosan polysulfate
- Amlexanox
- Heparin
- Sucrosofate
- Formic acid
- O2-Sulfo-Glucuronic Acid
- N,O6-Disulfo-Glucosamine
- Naphthalene Trisulfonate
- Pazopanib
- 5-aminonaphthalene-2-sulfonic acid
- Foreskin fibroblast (neonatal)
- Foreskin keratinocyte (neonatal)
|
|
|
FGF10 |
fibroblast growth factor 10 |
- PI3K Cascade
- PIP3 activates AKT signaling
- FGFR1b ligand binding and activation
- FGFR2b ligand binding and activation
- Activated point mutants of FGFR2
- Regulation of gene expression in early pancreatic precursor cells
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Downstream signaling of activated FGFR1
- SHC-mediated cascade:FGFR1
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Signaling by FGFR2 in disease
- FGFRL1 modulation of FGFR1 signaling
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
- Aplasia of lacrimal and salivary glands
- Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
|
|
FGF17 |
fibroblast growth factor 17 |
|
|
|